Legal Notice

Get more tools and info

For US Consumers

Onglyza Home Page

Understanding Onglyza

Onglyza Possible
Side Effects

Getting Started With Onglyza

How to Take Onglyza

Talking With Your Doctor
About Onglyza

Onglyza Savings Program

Onglyza FAQs

Legal Notice

TEXT

Acceptance of Agreement

Your access to and use of the Onglyza.com Web site (the “Site”) is subject to the following terms and conditions and all applicable laws. By accessing and browsing the Site, you accept and agree to, without limitation or qualification, the terms and conditions set forth herein with respect to your access and use of the Site.

Scope of Use

Bristol-Myers Squibb and AstraZeneca maintain the Site for your personal information, education, and communication. Please feel free to browse the Site. You may download material displayed on the Site for noncommercial, personal use only, provided you maintain all copyright and other proprietary notices or disclaimers contained on the materials. You may not, however, distribute, modify, transmit, reuse, repost, or use the content of the Site for public or commercial purposes, including the text and images, without Bristol-Myers Squibb or AstraZeneca’s written permission. You understand that Bristol-Myers Squibb and AstraZeneca make no representation that the information in the Site is appropriate or available for use in locations outside of the United States, and access to this Site from territories where the content of the Site may be illegal or inappropriate is unauthorized and at your own risk. Those who choose to access the Site from other locations do so on their own initiative and are responsible for compliance with applicable local laws.

No Medical Advice

The Site does not provide medical advice. With limited exception, Bristol-Myers Squibb and AstraZeneca products are available only by prescription from a licensed healthcare professional. Bristol-Myers Squibb and AstraZeneca are not engaged in rendering medical or similar professional services or advice, and the information provided on the Site is not intended to replace medical advice offered by a healthcare provider. If you desire or need such services or advice, you should promptly consult a physician or professional healthcare provider.

Product Information

The product information provided on the Site is intended only for residents in the United States. The Site and its links may, however, contain information about products that may or may not be available in any particular country, territory, or region of the world (including the United States), may be available under different trademarks in different countries, and, where applicable, may be approved or cleared by a government regulatory body for sale or use with different indications and restrictions in different countries. You should not construe anything on the Site as a promotion or solicitation for any product or service or for the use of any product or service that is not authorized by the laws and regulations of the country where you are located, including the United States. For specific information about particular products, you should refer to the full prescribing information as approved by the relevant governmental authority of the country where you are located. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.

Copyright Protection

You should assume that everything you see or read on the Site is copyrighted, unless otherwise noted, and may not be used except as provided in these terms and conditions or in the text on the Site without the written permission of Bristol-Myers Squibb and/or AstraZeneca. Bristol-Myers Squibb and/or AstraZeneca neither warrant nor represent that your use of materials displayed on the Site will not infringe rights of third parties not owned by or affiliated with Bristol-Myers Squibb or AstraZeneca.

Trademarks and Other Intellectual Property

The trademarks, trade names, logos, and service marks (collectively the “Trademarks”) displayed on the Site are registered and unregistered Trademarks of Bristol-Myers Squibb and/or AstraZeneca and others. This Site may also contain other intellectual property of Bristol-Myers Squibb and/or AstraZeneca. Nothing contained on the Site should be construed as granting, by implication, estoppel, or otherwise, any license or right to use any Trademark or other intellectual property contained on the Site without the written permission of Bristol-Myers Squibb and/or AstraZeneca or such third party that may own the Trademarks or other intellectual property contained on the Site. Your use of the Trademarks displayed on the Site, or any other content on the Site, except as provided in these terms and conditions, is strictly prohibited. You are also advised that Bristol-Myers Squibb and AstraZeneca will aggressively enforce their intellectual property rights to the fullest extent of the law, including the seeking of criminal prosecution.

Exclusion of Warranty

While Bristol-Myers Squibb and AstraZeneca use reasonable efforts to include accurate and up-to-date information in the Site, Bristol-Myers Squibb and AstraZeneca make no warranty or representation as to its accuracy. Bristol-Myers Squibb and AstraZeneca assume no liability or responsibility for any errors or omissions in the content of the Site. Without limiting the foregoing, everything on the Site is provided to you “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. Please note that some jurisdictions may not allow the exclusion of implied warranties, so some of the above exclusions may not apply to you. Check your local laws for any restrictions or limitations regarding the exclusion of implied warranties.

Limitation of Liability

Your use of and browsing in the Site are at your risk. Neither Bristol-Myers Squibb nor AstraZeneca nor any other party involved in creating, producing, or delivering the Site is liable for any direct, incidental, consequential, indirect, or punitive damages arising out of your access to, or use of, the Site. Bristol-Myers Squibb and AstraZeneca assume no responsibility, and shall not be liable for, any damages to, or viruses that may infect, your computer equipment or other property on account of your access to, use of, or browsing in the Site or your downloading of any materials, data, text, or images from the Site.

Prohibited Transmissions

Certain areas of the Site may enable you to access online forums and to submit e-mails or otherwise provide feedback to Bristol-Myers Squibb and AstraZeneca. Bristol-Myers Squibb and AstraZeneca do not endorse, and specifically disclaim, any responsibility or liability for any content in these fora. You may not post or transmit any unlawful, threatening, libelous, defamatory, obscene, indecent, inflammatory, pornographic, or profane material or any material that could constitute or encourage conduct that would be considered a criminal offense, give rise to civil liability, or otherwise violate any law. In addition, you are prohibited from posting or transmitting any information that (a) infringes the rights of others or violates their privacy or publicity rights, (b) is protected by copyright, trademark, or other proprietary right, unless with the express written permission of the owner of such right, (c) contains a virus, bug, or other harmful item, or (d) is used to unlawfully collude against another person in restraint of trade or competition. You shall be solely liable for any damages resulting from any infringement of copyright, trademark, or other proprietary right, or any other harm resulting from your use of the Site.

User Submissions

Any “personally identifiable information” in electronic communications to the Site is governed by the Site’s Privacy Statement. On the other hand, any communication or material you transmit to the Site by electronic mail or otherwise, including any data, questions, comments, suggestions, or the like is, and will be treated as, nonconfidential and nonproprietary. You understand that anything you transmit or post are the property of Bristol-Myers Squibb and AstraZeneca and may be used by Bristol-Myers Squibb and AstraZeneca or their respective affiliates for any purpose, including, but not limited to, reproduction, disclosure, transmission, publication, broadcast, and posting. Furthermore, Bristol-Myers Squibb and AstraZeneca own and are free to use any ideas, concepts, know-how, processes, or techniques contained in any communication you send to the Site for any purpose whatsoever including, but not limited to, developing, manufacturing, marketing, and selling products and service using such ideas, concepts, know-how, processes, or techniques.

Links to Other Sites

Bristol-Myers Squibb and AstraZeneca have not reviewed all of the sites linked to the Site and are not responsible for the content of any off-site pages or any other sites linked to the Site. Your linking to any other off-site pages or other sites is at your own risk. Once you link to another site, please be sure to review the legal notice and privacy statement of the new site. It may be different from those governing this Site.

Governing Law

This Agreement and its performance shall be governed by the laws of the state of New Jersey, United States of America, without regard to its conflict of laws provisions. You consent and submit to the exclusive jurisdiction of the state and federal courts located in the state of New Jersey, United States of America, in all questions and controversies arising out of your use of the Site and this Agreement. To the extent allowed by applicable law, any claim or cause of action arising from or relating to your access or use of the Site must be brought within two (2) years from the date on which such claim or action arose or accrued.

Modification of Agreement

Bristol-Myers Squibb and AstraZeneca may, at any time, revise the terms and conditions of this Agreement governing use of the Site. If any terms and conditions contained in this Legal Notice are changed, the amended notice will be posted on the Site. You are bound by any such revisions and should, therefore, periodically review these terms and conditions.

IMPORTANT SAFETY INFORMATION
for ONGLYZA (saxagliptin)

Do not take ONGLYZA (saxagliptin) if you are allergic to any of its ingredients. Serious allergic reactions can occur with ONGLYZA and may include swelling of the face, lips or throat, difficulty swallowing or breathing, swelling of the skin, hives, rash, itching, flaking, or peeling. If you have these symptoms, stop taking ONGLYZA and contact your doctor right away.

Serious side effects can happen to people taking ONGLYZA, including inflammation of the pancreas (pancreatitis) which may be severe and lead to death. Before taking ONGLYZA, tell your doctor if you ever had pancreatitis, gallstones, history of alcoholism, or high triglyceride levels. Stop taking ONGLYZA and contact your doctor right away if you have pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen through to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis.

WHAT IS ONGLYZA?

ONGLYZA (saxagliptin) is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

ONGLYZA should not be used to treat people with type 1 diabetes or diabetic ketoacidosis (increased ketones in the blood or urine).

If you have had inflammation of the pancreas (pancreatitis), it is not known if you have a higher chance of getting pancreatitis while taking ONGLYZA.

When ONGLYZA is used with certain other diabetes medicines to treat high blood sugar, such as a sulfonylurea or insulin, the risk of low blood sugar (hypoglycemia) is higher. Symptoms of low blood sugar include shaking, hunger, sweating, headache, rapid heartbeat, change in mood, and change in vision. Follow your doctor’s instructions for treating low blood sugar.

When ONGLYZA is used with a thiazolidinedione (TZD), such as pioglitazone or rosiglitazone, to treat high blood sugar, peripheral edema (fluid retention) may become worse. If you have symptoms of peripheral edema, such as swelling of hands, feet, or ankles, call your doctor.

The most common side effects with ONGLYZA include upper respiratory tract infection, urinary tract infection, and headache.

Your doctor should test your blood to measure how well your kidneys are working before and during treatment with ONGLYZA. You may need a lower dose if your kidneys are not working well.

Tell your doctor if you start or stop taking other medications, including antibiotics, antifungals or HIV/AIDS medications, as your doctor may need to change your dose of ONGLYZA.

Tell your doctor if you are pregnant, breast-feeding, or plan to become pregnant or breast-feed.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click here for Medication Guide, and click here for US Full Prescribing Information for ONGLYZA (saxagliptin).

This product information is intended for US customers only.
ONGLYZA^® is a trademark of Bristol-Myers Squibb Company. ©2012 Bristol-Myers Squibb Company.
422US12WA13301 08/12 2028900

US Full Prescribing Information Medication Guide Unsubscribe Privacy Statement Legal Notice Site Map

Bristol-Myers Squibb Patient Assistance Foundation:
This non-profit organization provides assistance to
qualifying patients with financial hardship who generally
have no prescription insurance. Contact 1-800-736-0003
or visit www.bmspaf.org for more information.

Value Card Program for Onglyza^® (saxagliptin)

Program Details and Eligibility Requirements for Patients

You may be eligible for this offer if: (1) You are a resident of Puerto Rico or the United States who is 18 years of age or older and are insured by commercial insurance that does not cover the full cost of your prescription (you have a co-pay obligation); and (2) Your prescriptions are not covered in full or in part by any state or federally funded insurance program, including but not limited to Medicare, Medicaid, Medigap, Veterans Affairs (VA) or Department of Defense (DOD). Patients who move from commercial to state or federally funded prescription insurance will no longer be eligible for this offer.
Eligible patients with a co-pay (out-of-pocket expense) for a 30-day supply of Onglyza^® (saxagliptin) tablets of more than $10 who present an activated card together with a valid prescription for Onglyza tablets at the time of purchase may be able to receive up to $100 in savings per month. Savings not applicable to monthly out-of-pocket expenses of $10 or less.
The first activation of the card will be valid for 24 months. Every 12 months thereafter, patients will be required to renew eligibility in order to continue participating in the offer.
Your acceptance of this offer confirms that this offer is consistent with your insurance and that you will report the value received as may be required by your insurance provider.
Patients, pharmacists, and prescribers cannot seek reimbursement, from health insurance or any third party, for any part of the benefit received by the patient through this offer.
Card activation and use must take place by 12/31/2013. In accordance with Massachusetts law, program expiration date in MA is July 1, 2015.
Only valid in the United States and Puerto Rico; this offer is void where restricted or prohibited by law.
This offer is non-transferable, no substitutions are permissible, and offer cannot be combined with any other rebate/coupon, free trial or similar offer for the specified prescription.
Card may not be sold, purchased, traded, or counterfeited. Reproductions of this card are void.
Bristol-Myers Squibb and AstraZeneca reserve the right to discontinue or change this offer at any time without notice.
This offer is not conditioned on any past, present or future purchase, including refills.
No membership fees. Card is not an insurance card.
By using this card, you and your pharmacist understand and agree to comply with these Program Details and Eligibility Requirements.